Entropy Neurodynamics Limited has released a press release.
Added Funding for 2023
Filed with ASX ·
6ix hasn’t read this filing yet.
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- EX1 to Receive $0.96m in Prepayment of R&D Tax Incentive
- Exopharm Received R&D Tax Incentive Refund
- Study results indicate exosomes safe for clinical pursuit
- FY2022 Appendix 4E and Annual Report
- EX1 to receive a further $0.48m in prepaid R&D Tax Incentive
Later from Entropy Neurodynamics
- Appendix 4D and Half Year Report for period 31 December 2022
- EX1 to Receive $0.431m in Prepayment of R&D Tax Incentive
- EX1 to Receive $1m from the Issue of Convertible Notes
- Disclosure Document - Rights Issue Prospectus
- Exopharm Limited announces Non-Renounceable Pro Rata Rights
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics